drugset / Trial / NCT01576341

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

NCT01576341

Phase 3 Completed 417 enrolled Sandoz
NaSingle-groupOpen-labelTreatment

Summary

The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)

Timeline

Start
2012-04
Primary completion
2014-10
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic Subcutaneous